Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

	Application Number Filing Date		10541909	
			2005-12-12	
First Named Inventor Boris		Bons	Y. Shekunov	
	Art Unit		1615	
	Examiner Name	Case	ey Shea Hagopian	
	Attorney Docket Number		FER-14670.001.002	

				Allomey Docket Number PER-146/0.001.0		.002	AUZ		
				U.S.	PATENTS			Remove	
Examiner Cite Patent Number Kind Code1		Issue Date	Name of Pat of cited Docu	entee or Applicant ument	Releva	Columns,Lines where int Passages or Release s Appear			
	1	5716558		1998-02-10	Nielsen et al.				
	2	6620351		2003-09-16	Gupta et al.				
If you wis	h to a	dd additional U.S. Pate	nt citatio	n information p	lease click the	Add button.	_	Add	
_			U.S.P	ATENT APPLI	CATION PUB	LICATIONS		Remove	_
Examiner Cite Publication Number Kind Code1		Publication Date	Name of Pat of cited Doc.	entee or Applicant ument	Releva	Columns,Lines wher int Passages or Rele s Appear			
lf you wis	1 h to a	dd additional U.S. Publ		plication citatio			d button	Add	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	To
	1								С
If you wis	h to a	dd additional Foreign P	atent Do	cument citation	information p	lease click the Add	button	Add	_
				-PATENT LIT				Remove	

Examiner Initials*	Cite No	nclude name of the author (in CAPITAL LETTERS), title of the article (when appro- book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume- rublisher, city and/or country where published.		Ţs			
	1	CHATTOPADHYAY, P. and GUPTA, R., Production of Antibiotic Nanoparticles Using Supe Antisolvent with Enhanced Mass Transfer, Ind. Eng. Chem. Res., 2001, Vol. 40, pp. 3530-3					
	2	CHATTCPROFIVAY, P. and GUPTA, R. Protein Nanoparticles Formation by Supercritical Antisolvent with Enhanced Mass Transfer, AIChE Journal, February 2002, Vol. 48, No. 2, pp. 235-244.					
If you wis	h to a	additional non-patent literature document citation information please click the Add	button Add				
EXAMINER SIGNATURE							
Examiner	Signa	re Date Considered					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a							

16e Kind Code of USPTO Potent Documents at yeary USPTO_CODY or MEPP 901.04. 2 filter of licit that issued the document, by the involved own (MPD Standard ST.3). 3 for Just purpose patient found counters, the orbidation of the year of the register or temperature precede the sent ancher of the patient document. 4 find of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 2 Applicant is to place a check mark here if Exhibit familiases benefication is attached.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10541909
Filing Date		2005-12-12
First Named Inventor	Boris	Y. Shekunov
Art Unit		1615
Examiner Name	Case	y Shea Hagopian
Attorney Docket Numb	er	FER-14670.001.002

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
_	information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c).

See attached certi		

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Randolph E. Digges, III/	Date (YYYY-MM-DD)	2006-04-21
Name/Print	Randolph E. Digges, III	Registration Number	40590

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is foll field and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenan's Afford, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.32.511.450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. 0. Box 1450, Alexandria, V.32.311.450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.